GXI.DE Stock Today: February 12 – Audit Probe Triggers 31% Plunge

Gerresheimer stock tumbled about 31% today after the company delayed its annual and consolidated results. Management said a second auditor is reviewing possible IFRS accounting issues around revenue recognition and inventory valuation. The company also cut its 2025 EBITDA margin guidance to 16.5–17.5% from 18.5–19.0% and warned of €220–240 million in non-cash impairments. For German investors, this combination of an earnings delay and lower profitability targets raises near-term risk and puts governance in focus, even as operations continue and liquidity remains available.

Audit review sparks selloff

Gerresheimer postponed publication of its annual and consolidated financial statements while a second auditor reviews potential IFRS breaches in revenue recognition and inventory valuation. The announcement drove the shares down roughly 31% to multi‑year lows as investors priced in added uncertainty and possible restatements. The company also flagged corrective actions and internal reviews now underway to address identified weaknesses. source

Accounting probes hit confidence because they can change reported earnings and equity, even when cash flows are initially unaffected. For Frankfurt traders and long‑term German savers, the issue is trust. Until the second auditor’s work is finished and the company publishes clean numbers, markets will likely demand a risk discount for Gerresheimer stock and keep volatility high.

Guidance cuts and impairments

Management lowered the 2025 EBITDA margin guidance to 16.5–17.5%, down from 18.5–19.0%. That implies reduced earnings power versus prior plans and narrows headroom on covenants if growth slows. The reset likely reflects tighter inventory controls and more conservative revenue timing. While demand from pharma customers remains, the margin step‑down suggests mix, costs, and compliance work will weigh through 2025.

Gerresheimer expects corrections to 2024 figures and non‑cash impairments of €220–240 million. These charges will not consume cash now but will reduce carrying values and could pressure leverage metrics. The focus areas are revenue recognition and inventory valuation under IFRS, so investors should watch gross margin, working capital, and any restated comparative periods once audited accounts are available.

Analyst take and valuation reset

Analysts flagged elevated uncertainty and the need to rebuild investor trust after the delay. Commentary points to possible further swings until the auditor’s review concludes and the new reporting date is set. Some see scope for longer repair work on controls and disclosure, which could keep a cap on the shares near term. source

Ahead of today’s drop, recent TTM data indicated a low price‑to‑sales ratio (about 0.29) and an EV/EBITDA near 7x, levels that often imply cyclical or governance risk. After a 31% decline, headline multiples may look cheaper, but that can be a value trap if margins reset lower or if restatements cut historical earnings for Gerresheimer stock.

What to watch next

Investors should track the second auditor’s findings, the new timeline for audited statements, and detailed remediation plans for internal controls. Watch for updates on asset measures too, including the planned sale of Centor Inc., USA, which could support deleveraging. For Germany‑based holders of GXI.DE, company briefings and any covenant disclosures will be crucial signals.

Volatility is likely to remain high until audited numbers and guidance stabilize. Consider smaller position sizes, wider stop‑loss levels, and staged entries rather than lump‑sum buys. For fundamental screens, prioritize cash conversion, working‑capital discipline, and the path back toward the prior margin range before adding exposure to Gerresheimer stock.

Final Thoughts

Today’s plunge in Gerresheimer stock reflects two core risks: an earnings delay tied to IFRS accounting issues and a reset to 2025 profitability. The margin guidance cut to 16.5–17.5% and expected €220–240 million in non‑cash impairments point to lower near‑term earnings and tighter balance‑sheet optics. For investors, patience and process matter now. Wait for the second auditor’s conclusions, the new reporting date, and clear remediation steps. Track working capital, gross margin, and cash conversion as the first proof points. Asset actions, including a Centor sale, could support deleveraging, but trust will rebuild only with audited, consistent disclosures and steady execution through 2025.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.